Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
This study is investigating a treatment called radiofrequency ablation (RFA) for a type of bile duct cancer known as cholangiocarcinoma. This cancer affects the tubes carrying bile from your liver. The study specifically focuses on cases where the cancer can't be removed with surgery. Patients taking part will already be receiving standard care, which includes chemotherapy and special tubes called stents to keep the bile ducts open. The main aim is to find out if adding RFA to this standard care can help reduce problems like infections or issues with the stents. Researchers also want to make sure RFA is a safe treatment option for these patients. They will compare two groups: one receiving RFA plus standard care, and another receiving standard care only.
De un vistazo
¿De qué trata este estudio?
This study is about a type of cancer called cholangiocarcinoma, which affects the bile ducts – these are little tubes in your liver that carry a fluid called bile. Sometimes, this cancer can block these important tubes. When the cancer can't be fully removed with surgery, doctors look for other ways to help patients.
Patients in this study will already be getting the usual treatments for their condition. This includes chemotherapy, which are medicines to fight the cancer throughout the body, and something called a stent. A stent is a small tube placed inside the bile duct to keep it open and help bile flow freely. The study wants to see if adding another treatment called radiofrequency ablation (RFA) can be beneficial.
RFA uses heat generated by radio waves to destroy cancer cells in the bile duct. Researchers want to find out if adding this RFA treatment, alongside chemotherapy and stents, can reduce common problems that these patients face. These problems can include infections, delays in chemotherapy, or issues with the stents. They also want to make sure that RFA is a safe option for people with this type of cancer.
Puntos clave
- The study investigates radiofrequency ablation (RFA) for bile duct cancer that cannot be removed by surgery.
- It aims to see if adding RFA reduces complications for patients already on chemotherapy and with stents.
- Researchers will also check if RFA is a safe treatment for this patient group.
- Participants will either receive RFA plus standard care or standard care alone.
- You must be 18 or older and meet specific health criteria to be included.
¿Quién puede ser elegible?
To join this study, you need to be an adult aged 18 or over. You must have a type of bile duct cancer (cholangiocarcinoma) that doctors can't remove with surgery, and you should already be receiving or planning to receive chemotherapy and have a stent placed in your bile duct.
Your general health should be good enough to take part, and your medical team will assess this. You shouldn't have had RFA for this cancer before, and you shouldn't have had a stent replaced in the last three months (though you can join if it's your very first stent or if it was placed within the last three months).
There are also some medical conditions that would prevent you from joining, such as severe heart problems or certain mental health conditions that would make it difficult to understand the study information.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- ¿Tienes 18 años o más?
- Do you have bile duct cancer (cholangiocarcinoma) that cannot be removed by surgery?
- Are you receiving or going to receive chemotherapy and have a stent in your bile duct?
- Have you NOT had radiofrequency ablation (RFA) for this cancer before?
- Do you feel generally well enough, with no major heart problems or other severe illnesses?
¿En qué consiste la participación?
If you decide to take part in this study, you will first sign a form saying you understand and agree to participate. All participants will receive the standard treatments, which include chemotherapy and having a stent placed to keep your bile duct open. You will then be put into one of two groups: one group will receive an additional treatment called radiofrequency ablation (RFA), and the other group will not.
The RFA procedure involves using a thin catheter (a small tube) to deliver heat to the cancer cells in your bile duct, helping to destroy them. The study team will monitor you closely throughout the treatment period. This will involve regular check-ups, assessments, and possibly some scans or blood tests, similar to what you would have as part of your normal care. The total duration of your participation in the study will depend on your treatment plan and follow-up schedule, which your doctor will explain in detail.
Riesgos y beneficios potenciales
Ubicaciones (1)
- University Medical Center Hamburg-EppendorfCódigo postal verificadoHamburgo, Alemania
Preguntas comunes
What is radiofrequency ablation (RFA)?
RFA is a procedure that uses heat from radio waves to destroy cancer cells in your bile duct.
Will I still get my normal cancer treatment?
Yes, all participants in this study will receive the standard treatments, including chemotherapy and a bile duct stent.
Is RFA a new treatment?
RFA has been used for various conditions, and this study aims to understand its specific benefits and safety for this type of bile duct cancer.
What if I decide I don't want to be in the study anymore?
You can leave the study at any time, for any reason. This will not affect the usual medical care you receive.
¿Cuánto tiempo durará el estudio para mí?
The exact length of your participation will depend on your individual treatment plan and how long doctors need to keep track of your progress. Your doctor will explain this to you.
Cómo obtener más información
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.